437 results on '"Battaglin, Francesca"'
Search Results
52. Supplementary Table S2 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
53. Supplementary Figure S1 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
54. Supplementary Figure from Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
55. Supplementary Tables from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
56. Supplementary Methods from Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
57. Supplementary Table from Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
58. Abstract P4-08-06: Clock Genes in Breast Cancer
59. The role of gene expression of CDC37 in colorectal cancer (CRC).
60. Tissue factor expression in colorectal cancer.
61. Molecular correlates of DSCR1 expression in colorectal cancer (CRC).
62. SETD2 gene expression and the molecular landscape of colorectal cancer (CRC).
63. Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2 (HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC).
64. Management of Advanced Small Bowel Cancer
65. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
66. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
67. Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials
68. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin‐based chemotherapy in patients with metastatic colorectal cancer
69. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions
70. Landscape of endocytosis pathway in colorectal cancer (CRC).
71. Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.
72. Comprehensive profiling of clock genes expression in colorectal cancer (CRC).
73. Comprehensive characterization of PTPRT expression in colorectal cancer (CRC).
74. Characterization of NY-ESO-1 gene expression in gastric cancer (GC).
75. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
76. Characterization of TIM3 and its ligands in colorectal cancer.
77. DEFB1 gene expression and the molecular landscape of colorectal cancer (CRC).
78. Claudin 18 (CLDN18) gene expression and related molecular profile in gastric cancer (GC).
79. Molecular correlates of MAEA expression in colorectal cancer (CRC).
80. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
81. Hippo pathway signaling associated with immune cell trafficking in colorectal cancer.
82. The role of germline polymorphisms in genes involved in the antioxidant system to predict the efficacy of cetuximab for patients with metastatic colorectal cancer (mCRC) enrolled in FIRE-3 trial.
83. The role of genetic variants involved with ferroptosis regulator genes in predicting outcomes in patients (pts) with RAS-mutant metastatic colorectal cancer (mCRC): Data from MAVERICC and TRIBE trials.
84. LRP1B and GRM3 expression in colorectal cancer.
85. Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.
86. fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing
87. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer
88. Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer
89. Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing
90. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
91. Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
92. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer
93. Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.
94. High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.
95. Globo H expression in metastatic colorectal cancer (CRC).
96. The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.
97. Comprehensive characterization of neurotransmitters and neuronal signaling (NT) pathway alterations in colorectal cancer (CRC).
98. Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC).
99. Association of high gene expression levels of ARF6 with the immune microenvironment and prediction of poor outcomes.
100. Germline polymorphisms in genes maintaining replication fork to predict the efficacy of oxaliplatin and irinotecan in metastatic colorectal cancer (mCRC) patients enrolled in MAVERICC trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.